We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.99%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$725M
AUM Growth
+$66.7M
Cap. Flow
+$16.4M
Cap. Flow %
2.26%
Top 10 Hldgs %
41.88%
Holding
145
New
38
Increased
32
Reduced
27
Closed
36

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$25.1M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.4M
3
AMGN icon
Amgen
AMGN
+$17.7M
4
BLUE
bluebird bio
BLUE
+$12.8M
5
VTRS icon
Viatris
VTRS
+$11M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$28.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.3M
3
SHPG
Shire pic
SHPG
+$11.3M
4
FOLD
Amicus Therapeutics
FOLD
+$9.93M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.8M

Sector Composition

Rank Sector Weight
1 Healthcare 72.21%
2 Technology 6.12%
3 Financials 1.97%
4 Industrials 1.58%
5 Consumer Discretionary 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NERV icon
26
Minerva Neurosciences
NERV
$185M
$6.77M 0.93%
102,515
+5,640
+6% +$343K
ALDX icon
27
Aldeyra Therapeutics
ALDX
$92.9M
$6.73M 0.93%
846,935
-162,196
-16% -$1.29M
KURA icon
28
Kura Oncology
KURA
$800M
$6.41M 0.88%
351,953
+21,953
+7% +$372K
SODA
29
DELISTED
SodaStream International Ltd
SODA
$6.29M 0.87%
+73,762
New +$6.66M
MLNT
30
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$6.25M 0.86%
196,898
+148,119
+304% +$5.33M
NICE icon
31
Nice
NICE
$5.79B
$6.23M 0.86%
60,043
-7,715
-11% -$781K
KDMN
32
DELISTED
Kadmon Holdings, Inc.
KDMN
$6.2M 0.85%
1,552,846
+62,846
+4% +$245K
QURE icon
33
uniQure
QURE
$3.03B
$5.76M 0.79%
152,490
+24,890
+20% +$797K
ARRY
34
DELISTED
Array Biopharma Inc
ARRY
$5.7M 0.79%
339,804
-65,196
-16% -$1.04M
ADMS
35
DELISTED
Adamas Pharmaceuticals
ADMS
$5.52M 0.76%
213,625
-121,875
-36% -$3.37M
BHVN
36
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$5.43M 0.75%
137,388
+6,288
+5% +$200K
SYRE icon
37
Spyre Therapeutics
SYRE
$8.54B
$5.39M 0.74%
+20,365
New +$5.01M
V icon
38
Visa
V
$684B
$5.35M 0.74%
40,401
– –
ASND icon
39
Ascendis Pharma A/S
ASND
$16B
$5.19M 0.72%
78,048
-17,426
-18% -$1.15M
LRMR icon
40
Larimar Therapeutics
LRMR
$397M
$4.91M 0.68%
+40,000
New +$3.4M
RETA
41
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$4.76M 0.66%
136,044
-88,956
-40% -$2.71M
AUTL
42
Autolus Therapeutics
AUTL
$407M
$4.72M 0.65%
+176,045
New +$4.65M
CARM
43
DELISTED
Carisma Therapeutics
CARM
$4.63M 0.64%
+118,853
New +$5.24M
WAB icon
44
Wabtec
WAB
$49.1B
$4.59M 0.63%
+46,564
New +$4.33M
WHWK
45
Whitehawk Therapeutics
WHWK
$190M
$4.58M 0.63%
+73,570
New +$4.45M
CYPH
46
Cypherpunk Technologies Inc
CYPH
$62.9M
$4.49M 0.62%
49,914
+7,205
+17% +$591K
MA icon
47
Mastercard
MA
$502B
$4.47M 0.62%
22,760
+6,235
+38% +$1.17M
SRRK icon
48
Scholar Rock
SRRK
$5.67B
$4.43M 0.61%
+283,997
New +$5.33M
CTIC
49
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$4.36M 0.6%
874,407
+40,774
+5% +$178K
CSCO icon
50
Cisco
CSCO
$457B
$4.3M 0.59%
+100,000
New +$4.37M
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2018 Portfolio in Review

As of Q2 2018, Sphera Funds Management held 145 positions worth $725M, up 10% from $659M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sphera Funds Management's Q2 2018 filing shows 38 new, 32 increased, 27 reduced and 36 closed positions. Its largest new stake was Gilead Sciences: 355,000 shares worth $25.1M. The largest sale was Celgene Corp, an estimated $28.5M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 75% a quarter earlier, followed by Technology and Financials.

  • Sphera Funds Management's largest Q2 2018 buy was Gilead Sciences: 355,000 shares worth $25.1M.
  • Sphera Funds Management added most to Viatris in Q2 2018, an estimated $11M increase.
  • Sphera Funds Management's biggest Q2 2018 reduction was Shire pic, cutting an estimated $11.3M.
  • Sphera Funds Management fully exited Celgene Corp in Q2 2018, selling an estimated $28.5M.
  • Sphera Funds Management's ten largest holdings make up 42% of its $725M portfolio in Q2 2018.
  • Sphera Funds Management opened 38 new positions and closed 36 in Q2 2018.
  • Sphera Funds Management's portfolio value rose 10% quarter-over-quarter to $725M.

Based on Sphera Funds Management's 13F filing for Q2 2018, filed 13 Aug 2018.